Goodwin: BridgeBio Oncology Therapeutics Completes $200M Private Financing
May 07, 2024
May 07, 2024
BOSTON, Massachusetts, May 7 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised BridgeBio Pharma (Nasdaq: BBIO) on the completion of a $200 million private financing of its former subsidiary, TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) to accelerate the development of its oncology portfolio. The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Manag . . .
The Life Sciences team advised BridgeBio Pharma (Nasdaq: BBIO) on the completion of a $200 million private financing of its former subsidiary, TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) to accelerate the development of its oncology portfolio. The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Manag . . .